NCT01648257 - Relative Bioavailability Study of GSK1265744 Formulations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Infections, Human Immunodeficiency Virus and Hepatitis

Interventions

DRUG

GSK1265744 Na Salt Tablets

Each tablet contains 30 mg of GSK1265744 sodium salt and excipients.

DRUG

GSK1265744 Free Acid Nanomilled Capsules

Each capsule contains 30 mg of nanomilled and spray dried GSK1265744 free acid, blended with excipients.

DRUG

GSK1265744 Free Acid Micronized Capsules

Each capsule contains 30 mg of micronized GSK1265744 free acid, blended with excipients.

Trial Locations (1)

GSK Investigational Site, Overland Park